NFIA

nuclear factor I A, the group of Nuclear factor I family

Basic information

Region (hg38): 1:60865259-61462788

Links

ENSG00000162599NCBI:4774OMIM:600727HGNC:7784Uniprot:Q12857AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • chromosome 1p32-p31 deletion syndrome (Strong), mode of inheritance: AD
  • brain malformations with or without urinary tract defects (Strong), mode of inheritance: AD
  • chromosome 1p32-p31 deletion syndrome (Definitive), mode of inheritance: AD
  • brain malformations with or without urinary tract defects (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Brain malformations with or without urinary tract defectsADRenalThe condition can include renal anomalies such as hydronephrosis and vesicoureteral reflux and awareness may allow early management, which may help prevent or manage renal sequelaeNeurologic; Renal17530927; 24462883; 27081522

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the NFIA gene.

  • not provided (13 variants)
  • Chromosome 1p32-p31 deletion syndrome (4 variants)
  • Inborn genetic diseases (4 variants)
  • Brain malformations with or without urinary tract defects (2 variants)
  • NFIA-related disorder (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the NFIA gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
47
clinvar
3
clinvar
51
missense
4
clinvar
65
clinvar
6
clinvar
75
nonsense
10
clinvar
7
clinvar
2
clinvar
19
start loss
1
clinvar
1
clinvar
1
clinvar
3
frameshift
7
clinvar
10
clinvar
17
inframe indel
1
clinvar
4
clinvar
5
splice donor/acceptor (+/-2bp)
3
clinvar
1
clinvar
4
splice region
9
20
5
34
non coding
4
clinvar
31
clinvar
31
clinvar
66
Total 22 22 78 84 34

Variants in NFIA

This is a list of pathogenic ClinVar variants found in the NFIA region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
1-61077098-G-GAGGGGAGA Benign (Aug 03, 2018)1249368
1-61077220-A-G Benign (Jul 06, 2018)1227712
1-61077852-CT-C Likely benign (Sep 08, 2019)1214327
1-61077852-C-CT Benign (Jan 01, 2020)1231072
1-61081568-A-G Likely benign (Aug 20, 2019)1223209
1-61081946-G-A Uncertain significance (Jun 20, 2023)3360054
1-61081954-G-A Inborn genetic diseases Uncertain significance (Aug 09, 2021)2242153
1-61081983-G-A NFIA-related disorder Likely benign (Feb 28, 2023)3030877
1-61081990-C-T Uncertain significance (Dec 15, 2022)2505589
1-61082009-C-A Uncertain significance (Apr 04, 2023)2662449
1-61082038-C-T Inborn genetic diseases Uncertain significance (May 20, 2021)2230686
1-61082052-G-C Chromosome 1p32-p31 deletion syndrome Uncertain significance (Apr 05, 2020)1031169
1-61082594-CGCTG-C Benign (May 18, 2021)1296107
1-61082672-TTC-T Benign (Oct 21, 2019)1295689
1-61082762-C-A Uncertain significance (Dec 15, 2022)2505862
1-61082792-A-C Brain malformations with or without urinary tract defects Uncertain significance (Mar 06, 2023)2500353
1-61082793-T-C NFIA-related disorder Pathogenic/Likely pathogenic (Jul 21, 2024)546320
1-61082794-G-A Pathogenic (Jun 28, 2023)2571793
1-61082806-C-G Likely benign (Feb 04, 2022)1636804
1-61082806-C-T Likely benign (Jan 06, 2023)2820503
1-61082806-CTG-C NFIA-related disorder Likely pathogenic (Sep 25, 2024)3344300
1-61082809-T-C Likely benign (Dec 11, 2023)2083104
1-61082814-C-G Inborn genetic diseases Likely benign (Nov 27, 2023)3197468
1-61082816-C-T Pathogenic (Jul 08, 2023)2738411
1-61082817-A-G Uncertain significance (Jul 30, 2022)2011003

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
NFIAprotein_codingprotein_codingENST00000371189 12597535
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.000.00040700000.00
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense3.231583210.4920.00001813571
Missense in Polyphen44137.520.319961539
Synonymous-0.1141231211.010.000006971123
Loss of Function4.85231.20.06400.00000202323

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.000.00
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Recognizes and binds the palindromic sequence 5'- TTGGCNNNNNGCCAA-3' present in viral and cellular promoters and in the origin of replication of adenovirus type 2. These proteins are individually capable of activating transcription and replication.;
Disease
DISEASE: Brain malformations with or without urinary tract defects (BRMUTD) [MIM:613735]: A syndrome characterized by corpus callosum hypoplasia or agenesis, hydrocephalus or ventricular enlargement, developmental delay, and urinary tract defects. {ECO:0000269|PubMed:24462883, ECO:0000269|PubMed:27081522}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Gene expression (Transcription);RNA Polymerase III Transcription Termination;FOXA1 transcription factor network;RNA Polymerase III Abortive And Retractive Initiation;RNA Polymerase III Transcription (Consensus)

Recessive Scores

pRec
0.361

Intolerance Scores

loftool
0.0782
rvis_EVS
-0.54
rvis_percentile_EVS
20.26

Haploinsufficiency Scores

pHI
0.350
hipred
Y
hipred_score
0.773
ghis
0.614

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.563

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Nfia
Phenotype
growth/size/body region phenotype; cellular phenotype; craniofacial phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);

Gene ontology

Biological process
negative regulation of transcription by RNA polymerase II;DNA replication;regulation of transcription, DNA-templated;viral genome replication;positive regulation of transcription by RNA polymerase II;synapse maturation;ureter development
Cellular component
nucleus;nucleoplasm;cell junction
Molecular function
RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;chromatin binding;DNA-binding transcription factor activity;transcription factor binding